Cargando…

Clinical Efficacy of Bendamustine Plus Rituximab (BR) for B-cell Relevant Indolent Non-Hodgkin's Lymphoma and Role of β2-MG in Predicting the Efficacy of BR Regimen: A Real-World Retrospective Study in China

BACKGROUND: Domestic bendamustine has been approved for appearing on the market in China in the past two years. The report on bendamustine plus rituximab (BR) in the treatment of Chinese B-cell-associated indolent non-Hodgkin's lymphoma (iNHL) has not yet been published. This study probed into...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Yujie, He, Donghua, He, Jingsong, Huang, Weijia, Yang, Yang, Cai, Zhen, Zhao, Yi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8794694/ https://www.ncbi.nlm.nih.gov/pubmed/35096126 http://dx.doi.org/10.1155/2022/1080879

Ejemplares similares

Rituximab and Bendamustine (BR) Compared with Rituximab, Bendamustine, and Cytarabine (R-BAC) in Previously Untreated Elderly Patients with Mantle Cell Lymphoma
por: Bega, Giulia, et al.
Publicado: (2021)

Bendamustine: Safety and Efficacy in the Management of Indolent Non-Hodgkins Lymphoma
por: Tageja, Nishant
Publicado: (2011)

Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone
por: Cheson, Bruce D., et al.
Publicado: (2016)

The role of bendamustine in the treatment of indolent non-Hodgkin lymphoma
por: Aldoss, Ibrahim T, et al.
Publicado: (2009)

Bendamustine HCL for the treatment of relapsed indolent non-Hodgkin’s lymphoma
por: Weide, Rudolf
Publicado: (2008)

An evaluation of the potential for drug–drug interactions between bendamustine and rituximab in indolent non-Hodgkin lymphoma and mantle cell lymphoma
por: Darwish, Mona, et al.
Publicado: (2014)

Solid-liquid equilibria in relevant subsystems of LiBr-NaBr-KBr-MgBr(2)-CaBr(2)-H(2)O system at 298.15 K
por: Cui, Ruizhi, et al.
Publicado: (2023)

P1193: POLATUZUMAB, BENDAMUSTINE & RITUXIMAB (POLA-BR) EFFICACY IN RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA (RRDLBCL) TRIAL-INELIGIBLE PATIENTS: AN AUSTRALIAN LYMPHOMA REGISTRY (LARDR) STUDY
por: Shaw, Briony, et al.
Publicado: (2023)

Pegfilgrastim in primary prophylaxis of febrile neutropenia following frontline bendamustine plus rituximab treatment in patients with indolent non-Hodgkin lymphoma: a single center, real-life experience
por: Cerchione, Claudio, et al.
Publicado: (2016)

Classic Hodgkin Lymphoproliferative Diseases Clonally Unrelated to B-Chronic Lymphocytic Leukemia Successfully Treated with Bendamustine Plus Rituximab
por: Rai, Shinya, et al.
Publicado: (2018)

Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202
por: Ruppert, Amy S., et al.
Publicado: (2021)

PB2080: EFFICACY AND SAFETY OF BENDAMUSTINE-BASED REGIMENS AS FIRST-LINE TREATMENT FOR INDOLENT B-CELL NON-HODGKIN LYMPHOMA: A PROSPECTIVE, MULTICENTER, REAL-WORLD STUDY IN CHINA
por: Li, S., et al.
Publicado: (2022)

High efficacy of BGD (bendamustine, gemcitabine, and dexamethasone) in relapsed/refractory Hodgkin Lymphoma
por: Swoboda, Ryszard, et al.
Publicado: (2021)

Preparation of the Key Dolutegravir Intermediate via MgBr(2)-Promoted Cyclization
por: Kong, Jiahui, et al.
Publicado: (2021)

Phase Equilibria in Ternary System CsBr-AgBr-InBr(3)
por: Kamilov, Rustam K., et al.
Publicado: (2023)

RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma
por: Nowakowski, Grzegorz S., et al.
Publicado: (2023)

Venetoclax plus bendamustine-rituximab or bendamustine-obinutuzumab in chronic lymphocytic leukemia: final results of a phase Ib study (GO28440)
por: Stilgenbauer, Stephan, et al.
Publicado: (2020)

Evidence of bendamustine plus rituximab for old and frail patients with aggressive B-cell lymphoma
por: Schalk, Enrico, et al.
Publicado: (2023)

Copanlisib plus rituximab combination therapy vs. rituximab monotherapy for relapsed indolent non-Hodgkin lymphoma: a cost-effectiveness analysis
por: Tang, Xiao, et al.
Publicado: (2022)

Correction to: RE‑MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola‑BR), CAR‑T therapies, and lenalidomide/rituximab (R2) based on real‑world data in patients with relapsed/refractory diffuse large B‑cell lymphoma
por: Nowakowski, Grzegorz S., et al.
Publicado: (2023)

Correction to: High efficacy of BGD (bendamustine, gemcitabine, and dexamethasone) in relapsed/refractory Hodgkin lymphoma
por: Swoboda, Ryszard, et al.
Publicado: (2021)

Golden Jubilee Photos<br> Particles for hospitals<br>
Publicado: (2004)

Heavy-ion production of (77)Br and (76)Br
por: McGuinness, Sean R., et al.
Publicado: (2021)

Successful Treatment of Factor X Deficiency in a Patient with Lymphoplasmacytic Lymphoma with Bendamustine Plus Rituximab Regimen: A Case Report and Literature Review
por: Rungjirajittranon, Tarinee, et al.
Publicado: (2021)

Bendamustine in the treatment of non-Hodgkin’s lymphomas
por: Hagemeister, Fredrick, et al.
Publicado: (2009)

Bendamustine plus rituximab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma
por: Murayama, Kayoko, et al.
Publicado: (2022)

Real-world evidence of cytomegalovirus reactivation in non-Hodgkin lymphomas treated with bendamustine-containing regimens
por: Pezzullo, Luca, et al.
Publicado: (2021)

In Search of a Double Perovskite in the Phase Triangle of Bromides CsBr-CuBr-InBr(3)
por: Kamilov, Rustam K., et al.
Publicado: (2023)

P639: ZANUBRUTINIB (ZANU) VS BENDAMUSTINE + RITUXIMAB (BR) IN PATIENTS (PTS) WITH TREATMENT-NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): EXTENDED FOLLOW-UP OF THE SEQUOIA STUDY
por: Munir, Talha, et al.
Publicado: (2023)

Fabrication of novel AgBr/Bi(24)O(31)Br(10) composites with excellent photocatalytic performance
por: He, Zuming, et al.
Publicado: (2018)

An unusual case of primary hepatic lymphoma with dramatic but unsustained response to bendamustine plus rituximab and literature review
por: Liao, Sih-Han, et al.
Publicado: (2017)

Long-term follow-up of rituximab plus bendamustine and cytarabine in older patients with newly diagnosed MCL
por: Tisi, Maria Chiara, et al.
Publicado: (2023)

A measurement of $\frac{BR(D_{s}^{+} \to K^{0}K^{+})}{BR(D_{s}^{+} \to \phi\pi^{+})}$ and $\frac{BR(D_{s}^{+} \to K^{0}K^{*+})}{BR(D_{s}^{+} \to \phi\pi^{+})}$
por: Giehl, I
Publicado: (1996)

Bendamustine/dexamethasone/rituximab: Cytomegalovirus reactivation : case report
Publicado: (2021)

Bendamustine/rituximab: COVID-19 pneumonia: case report
Publicado: (2021)

Bendamustine/rituximab: Neutropenia, fever and inflammation: case report
Publicado: (2022)

Isolated intracardiac recurrence of diffuse large B-cell lymphoma successfully treated with rituximab and bendamustine chemotherapy regimen
por: Chang, CH, et al.
Publicado: (2020)

Water-induced MAPbBr(3)@PbBr(OH) with enhanced luminescence and stability
por: Liu, Kai-Kai, et al.
Publicado: (2020)

Front-Line Therapy for Elderly Chronic Lymphocytic Leukemia Patients: Bendamustine Plus Rituximab or Chlorambucil Plus Rituximab? Real-Life Retrospective Multicenter Study in the Lazio Region
por: Autore, Francesco, et al.
Publicado: (2020)

Evolution of Br⋯Br contacts in enantioselective molecular recognition during chiral 2D crystallization
por: Yi, Zhen-Yu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_j7pik22bfdvi5ouuor72mqb21q